First Patient Enrolls in U.S. SALUS Trial Evaluating Direct Flow Medical, Inc. Transcatheter Aortic Heart Valve System

Published: Sep 10, 2013

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

SANTA ROSA, Calif.--(BUSINESS WIRE)--Direct Flow MedicalĀ®, Inc., a transcatheter heart valve company focused on improving patient outcomes, today announced the first patient enrollment in the U.S. SALUS clinical trial. The trial will study the Direct Flow Medical Transcatheter Aortic Heart Valve System, which encompasses a distinctive transcatheter aortic heart valve with a metal-free frame and flexible, low-profile delivery system designed to eliminate aortic regurgitation. The device is intended to improve the long term survivability of aortic stenosis patients by resolving the clinical issues associated with current commercial valves.

Help employers find you! Check out all the jobs and post your resume.

Back to news